Beacon Group’s Post

Our co-founder and CTO, Ilker Hacihaliloglu, has been recognized as one of the top 24 founders of 2024 by the FounderSquare Community! At PONS, we are on a mission to democratize medical imaging—bringing accessible, affordable, and advanced diagnostic tools to every corner of the world. Whether in rural areas, low-income communities, or underserved populations, we believe everyone deserves a fighting chance to detect and prevent diseases like cancer early, regardless of race, background, or wealth. Under Ilker Hacihaliloglu’s guidance, PONS has been at the forefront of leveraging AI-driven ultrasound technology, enabling early diagnostics and empowering caregivers with life-saving tools outside traditional hospital settings. Together, we are breaking barriers and ensuring medical imaging is a right, not a privilege. 💡 Here’s to bold innovation, impactful leadership, and creating a world where no life is lost too early due to preventable diseases. Let’s work together and strive for a healthier, more equitable future! 🚀 #TopFounder2024 #InnovationInHealthcare #AIForGood #DemocratizingHealthcare #EarlyDiagnostics #PONS #CTO #MedicalImaging #HealthcareForAll #ImpactDriven #CancerAwareness

For anyone looking for analogous inspiration on how you GTM with an AI product from business case (this is more of a “human” case if you know the why behind #BioticsAI) to solution launch, Robhy Bustami and BioticsAI have a great story. Check it out!

Quest Diagnostics and Sentara Health Plans have announced a strategic partnership to expand laboratory access in Virginia and Florida. Starting January 1, 2025, Quest will become the exclusive independent laboratory provider for Sentara Health Plans, offering clinical laboratory and anatomic pathology services to members in both states, including those in Sentara's AvMed business. The collaboration aims to enhance access to affordable lab testing for Sentara members while expanding Quest's patient service centre network in certain areas. Colin Drozdowski, President of Sentara Health Plans, emphasized that this partnership will provide innovative and comprehensive laboratory services to their members. Leah Timmerman, Senior Vice President of Health Plans at Quest Diagnostics, highlighted the company's role as a strategic collaborator in reducing healthcare costs while enhancing access, innovation, and quality. This partnership represents a significant expansion for Quest in the south-eastern US, particularly in Virginia, where its presence has been limited. The collaboration also includes plans to educate Sentara members and providers about the benefits of using Quest for testing instead of higher-cost, out-of-network options. https://lnkd.in/eJPgW9J5 Stay informed and ahead of the curve by following Practical Patient Care on LinkedIn for the latest industry news and insights! #PracticalPatientCare #HealthcarePartnership #LaboratoryServices #PatientAccess #AffordableHealthcare

Check out this webinar with our staff writer Annette Boyle tomorrow on pulsed field ablation.

🚀 Reflecting on an Incredible 2024 for PONS 🚀 As we close out 2024, we are beyond proud to look back on the monumental strides PONS has made this year, and we want to take a moment to celebrate these remarkable milestones! 🎉 2024 Highlights: 🌟 Being accepted to the Mayo Clinic Program to push the boundaries of medical imaging. 🌟 Collaborating with Chiesi Pharma, Memorial Sloan Kettering, and Johnson & Johnson Labs to shape the future of healthcare diagnostics. 🌟 Winning the UN WIPO Award for innovation, the EIT Europe Award for excellence, and the AARP AgeTech Award for revolutionizing healthcare for older adults. These collaborations and recognitions are a testament to the power of our AI-driven ultrasound technology, and the deep belief in our mission to democratize medical imaging. 💡 At PONS, we are committed to making medical imaging accessible to all, regardless of race, income, or location. Our technology empowers individuals with the tools for early diagnostics, enabling faster interventions and better health outcomes, especially for underserved populations. Together, we can ensure nobody loses a loved one too early due to preventable diseases. A huge THANK YOU to the incredible PONS team for your relentless dedication and unwavering belief in our vision. 🙏 We are also deeply grateful to our investors/advisors—SOSV, Conscious Venture Lab, and Harvey Castro, MD, MBA. Castro—for your steadfast support and guidance as we continue this exciting journey! 💙 Onwards and upwards, PONS team. The future is bright, and we are just getting started! 🔥 #PONS #MedicalImaging #HealthcareInnovation #AIForGood #EarlyDiagnostics #HealthcareForAll #Teamwork #Grateful #InvestorSupport #DemocratizingHealthcare #InnovationAwards #2024Achievements #VisionForTheFuture

🌟 Meet the minds behind the SQUEEZE project at the #EULAR2024 conference! 🌟  🔬 Dive deep with Karolina Anderle, lead of our #MethMax trial! The methotrexate dose/route optimisation trial coordinated by Medical University of Vienna, aims to optimize the #MTX dose and route. 📍 Join the conversation! Visit our booth and get a closer look at innovative strategies in #RA treatment through one of our three clinical trials, understand the impact of this specific trial and what it means for the future of #RheumatoidArthritis.  #HADEA #HorizonEurope #EUprojects #innovation #healthcare #InnovationInHealthcare #clinicaltrials 

🌟 Exciting News! Comprehensive Collaboration to Improve #AMD Care 🌟 We are thrilled to announce our partnership with Veonet to advance the care for patients with age-related macular degeneration (#AMD). 📅 RetInSight, a pioneer in #AI-based retinal disease analysis, and Veonet, a top network of #ophthalmology care centers in Germany, Switzerland, Netherlands, Spain, and the UK, are joining forces. This collaboration will integrate #RetInSight’s certified AI software solutions, #FluidMonitor and #GAmonitor, into Veonet’s clinical routine. These innovative tools provide eye doctors with easy-to-understand PDF reports, enhancing diagnostics and monitoring for #AMD patients, and ensuring efficient and effective patient management. 🔹 Corinna zur Bonsen-Thomas, CEO of RetInSight: “We are excited about this comprehensive collaboration with Veonet. Our #AI #technology will significantly improve #diagnostics, increase #productivity, and bolster #patient #confidence in their therapy.” 🔹 Prof. Dr. Ulrich Kellner, Veonet’s Medical Board Member: “With rising patient numbers and limited healthcare staff, #AI-based solutions are crucial for timely, efficient, and personalized #treatment. RetInSight’s software is key to future #patient #care, enabling standardized evaluations and personalized treatment plans.” 🌟 About the #RetInSight Software Solutions: ➡ Fluid Monitor: Precisely analyzes OCT images for #neovascularAMD #nAMD #wetAMD, providing instant visualized reports for disease assessment. ➡ GA Monitor: Precisely analyzes OCT images for #GeographicAtrophy #dryAMD, offering early and comprehensive disease activity and stage reports to support patient communication and treatment planning. 🌟 Together, RetInSight and Veonet are set to #revolutionize #AMD #care, ensuring #better #vision and #quality #of #life for #patients. Click here to read the full press release: https://lnkd.in/dcjgQvnY

We’re excited to announce that we’ll be attending #SCOPE2025! 🚀 From February 3–6, 2025, our Mighties—Dennis Akkaya, Heather Clancy, Danny den Hamer, Laura Hinton Cox, and Madeleine Carrier—will be in Orlando, Florida, joining over 3,500 experts in the #clinicaltrial space. 👏 ☀️This year’s program focuses on advances and innovative solutions across all aspects of clinical trial innovation, planning, management, operations, and investment. ➡️ This theme resonates deeply with our mission to transform and advance the clinical trial discovery and access process through our AI-driven platform —a centralized and secured solution that easily connects patients, physicians, trial sites, and BioPharma. By doing so, we aim to break down the barriers that prevent people from discovering and accessing all available treatments, including clinical trials. ☀️ 💚 Interested in knowing more about myTomorrows’ technology? Join us on Thursday, 6 February at 9.55 am for our presentation “A new way forward - Applying GenAI to solve the clinical trial recruitment conundrum at scale”. We’re incredibly excited to reveal the latest innovations in our tool! Stay tuned for more details about our session! 👉Are you attending too? Book a meeting with us: https://lnkd.in/evXTd97T #AI #SCOPE2025 #ClinicalTrials #Innovation #Networking #Biopharma #DigitalTransformation

It's #ClinicalTrialsDay in the USA! Let's celebrate the heroes of medical progress who work tirelessly to change outcomes for patients worldwide. Clinical trials are the engines driving innovation in healthcare. They allow us to test new treatments and therapies, paving the way for a healthier future for all. Today, we recognize the incredible dedication of the brilliant researchers who design and oversee these trials, and the participants who give the ultimate gift to patients. 👀 Have you seen our list of #radiotherapeutics under clinical development? At the foundation, we are committed to sharing the status of radiotherapeutic molecules from their early stages. Check it out here: https://buff.ly/3Xr8Sjc #CancerResearch #CancerAwareness

It started with a seemingly simple ambition: enabling medical professionals to share their reports with a single click. // In reality, this was not simple at all: Lifen invested huge technical and operational efforts. The result? An average time-saving of ⏳ 3 hours per day per medical secretary, and stronger collaboration between city practices and hospitals 🏥. 💪💪💪 🤩 Today, Lifen offers much more! After a pilot project with Gustave Roussy to build the LUCC multicenter cohort, aimed at characterizing lung cancer patients 🫁 (over 3,000 patients from 17 centers in under 9 months), Lifen is accelerating the development of Lifen DataLab: a solution to collect and structure real-world patient data for clinical research—a time-consuming and costly process today. Lifen and #France2030 (operated by Bpifrance) have just announced a €15M investment 💶 to boost the development of DataLab. The hospital environment and care pathways between city and hospital are notoriously complex, and large-scale adoption only happens when tools prove their worth in real-world settings. For healthcare entrepreneurs, focusing on solving one 'simple' problem on the ground, before moving to fancier ambitions seems to be the right approach 💡. Congratulations to Lifen co-founders Franck Le Ouay, Etienne Depaulis, and Alexandre Huckert for driving forward projects that are advancing medicine! Grateful to have you on board with 50 Partners Health! 🙌 Bravo to Lifen's clinical partners, institutional partners, and investors, who are making this happen! 👏 Benjamin Besse Pierre Moustial Jean-Marc Patouillaud Clara Chappaz Thibault Naline and many more 👏